CADLCandel Therapeutics, Inc.Signing up patients
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
Non-squamous, Non-Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 500 (planned)
- Started
- Jun 15, 2026
- Main results expected
- Oct 22, 2031
- Fully finished
- Oct 22, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival
Measured over: From date of randomization until date of death from any cause, assessed for a minimum of 24 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07660094 · record last updated 2026-06-22 · checked 2026-11-09 15:47 UTC